Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Prebiotic-supplemented partially hydrolysed cow's milk formula for the prevention of eczema in high-risk infants: a randomized controlled trial
Author: Boyle, R.
Tang, M.-K.
Chiang, W.
Chua, M.
Ismail, I.
Nauta, A.
Hourihane, J.
Smith, P.
Gold, M.
Ziegler, J.
Peake, J.
Quinn, P.
Rao, R.
Brown, N.
Rijnierse, A.
Garssen, J.
Warner, J.
Citation: Allergy, 2016; 71(5):701-710
Publisher: Wiley Online Library
Issue Date: 2016
ISSN: 0105-4538
Statement of
R. J. Boyle, M. L.‐K. Tang, W. C. Chiang, M. C. Chua ... M. Gold ... P. Quinn ... et al. (On behalf of the PATCH study investigators)
Abstract: Prevention guidelines for infants at high risk of allergic disease recommend hydrolysed formula if formula is introduced before 6 months, but evidence is mixed. Adding specific oligosaccharides may improve outcomes.To evaluate whether partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHF-OS) can prevent eczema in high-risk infants [ISRCTN65195597].We conducted a parallel-group, multicentre, randomized double-blind controlled trial of pHF-OS vs standard cow's milk formula. Infants with a family history of allergic disease were randomized (stratified by centre/maternal allergy) to active (n = 432) or control (n = 431) formula until 6 months of age if formula was introduced before 18 weeks. Primary outcome was cumulative incidence of eczema by 12 months in infants randomized at 0-4 weeks (375 pHF-OS, 383 control). Secondary outcomes were cumulative incidence of eczema by 12 or 18 months in all infants randomized, immune markers at 6 months and adverse events.Eczema occurred by 12 months in 84/293 (28.7%) infants allocated to pHF-OS at 0-4 weeks of age, vs 93/324 (28.7%) control (OR 0.98 95% CI 0.68, 1.40; P = 0.90), and 107/347 (30.8%) pHF-OS vs 112/370 (30.3%) control in all infants randomized (OR 0.99 95% CI 0.71, 1.37; P = 0.94). pHF-OS did not change most immune markers including total/specific IgE; however, pHF-OS reduced cow's milk-specific IgG1 (P < 0.0001) and increased regulatory T-cell and plasmacytoid dendritic cell percentages. There was no group difference in adverse events.pHF-OS does not prevent eczema in the first year in high-risk infants. The immunological changes found require confirmation in a separate cohort.
Keywords: Eczema; infant formula; oligosaccharides; hydrolysate; randomized controlled trial
Rights: © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1111/all.12848
Appears in Collections:Animal and Veterinary Sciences publications
Aurora harvest 8

Files in This Item:
File Description SizeFormat 
hdl_118490.pdfPublished version382.61 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.